Since Justin Trudeau’s election, the Canadian cannabis space has seen significant growth both in public and private sectors. The industry is gearing up for its entry into the legal recreational cannabis market set to open up by July 1, 2018.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 3% in June as continued losses in Canada closed out the Index’s second worst performing quarter since its inception in January 2015.
Insys Therapeutics is one of several biotechs developing cannabinoid drugs. Unlike most of these other companies, though, Insys has already won regulatory approval for its first cannabinoid — Syndros.
The results for Canopy Growth’s stock have been terrific so far, yielding a return of over 152% since inception. The stock has been performing well despite lacklustre results and frequent losses.
The Auscann Group Holdings Ltd share price has continued its strong run and is up a further 6% to 46 cents today. Why has it jumped? Let’s look to find out.
Canadian marijuana players have been rushing to invest and take strategic positions in the new Germany medical cannabis market since late 2016, and this trend is set to continue going forward.
One decision by a major bank could mean trouble in the not-too-distant future for marijuana stocks.
MedReleaf is one of less than four dozen licensed producers and retailers of medical cannabis products in Canada. The company was founded just four years ago, and it focuses on supplying dried cannabis, cannabis oils, and cannabis oil capsules to qualified medical patients in Canada.
If these headsets make ordering marijuana easier, which would in turn increase sales, this technology will be another boon for marijuana dispensary stocks.
Aurora Cannabis Inc. today is one of the pre-eminent marijuana producers listed on the TSX Venture Exchange with a market capitalization just shy of $750 million, making it the fourth-largest marijuana stock behind only GW Pharmaceuticals PLC- ADR, Canopy Growth Corp., and Aphria Inc.
Here’s why Scotts Miracle-Gro Company, GW Pharmaceuticals, and Canopy Growth Corporation are three stocks to buy if you’ve never bought a cannabis stock.
Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers that have some of their pipelines devoted to cannabinoid-type therapeutics or CB agonists and other portions devoted to non-cannabinoid medicines.
Warren Buffett is well known as the most successful investor of all time. Buffett spent his formative years under the tutelage of Benjamin Graham, who is known today as the “father of value investing.” Let’s see whether or not Aphria Inc. can pass Buffett’s mentor’s criteriea test.
Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
Mexican medical marijuana businesses and their investors will have a long time to wait before seeing profits from the newly legalized industry.
Though there are a number of direct players in the industry, some of the most surprising growth can be seen in emerging industry players. One such name is Scotts Miracle-Gro.
On July 1, 2017, Nevada will legalize the use and sale of recreational marijuana, which could be a catalyst for long-term gains for three cannabis stocks.
The industry and the Canopy Growth Corp. were going to be the next big thing for investors, but things have cooled down gradually over the past few months.
According to a press release from Health Canada in late May, big changes are coming to the country’s medical cannabis program.
On June 15, 2017, the United States Securities and Exchange Commission called hemp oil fraud on a public company, filing a complaint in federal court that claims CV Sciences (OTCQB:CVSI) , formerly known as CannaVEST, and its CEO, Michael Mona, Jr., intentionally overstated the company’s total assets.
The first cannabis stock ETF of its kind, the Horizons Marijuana Life Sciences Index ETF allows investors to own more than a dozen pot stocks through a single investment fund. Today, however, is a different story.
Medical Marijuana, Inc. holds the distinction of being the first publicly listed marijuana stock, and its diversity is rare, but is it worth investing in?
Thanks to a 2% gain to 49 cents today, the Cann Group Ltd (ASX: CAN) share price has now risen over 63% since hitting the ASX boards.
In late May, MedReleaf priced its public offering at just over $7 per share. The marijuana stock IPO raised a whopping $75 million. Unfortunately, things didn’t work out as planned for pot investors or MedReleaf.
Here is a novel concept could increase the safety of cannabis deliveries and be a boon for marijuana stocks: drone deliveries. Not only will drone deliveries increase safety, but they will also make delivery faster and more convenient.
On June 12, 2017, the MedMen Opportunity Fund, a California-based private equity fund focused on the legal marijuana industry, filed Form D with the United States Securities and Exchange Commission, indicating that it had raised approximately $60 million of its $100 million offering.
MedReleaf Corp. is the latest cannabis stock to hit the TSX. Could they be the spark to reignite the second wave of the green rush?
Aurora Cannabis Inc. has just announced another possible acquisition, and this time snatching up one of the world’s largest industrial hemp producers.
In April, investors were privy to the very first marijuana stock ETF, which debuted on the Toronto Stock Exchange with slightly more than a dozen holdings. This represented the very first time a basket fund was created for investors to easily diversify their pot-stock holdings. And last week, investors witnessed another marijuana first: the largest North American marijuana stock IPO of all-time.
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Oh, how the mighty have fallen. Shares of Canopy Growth Corp. have dropped by over $6 a share, or 47.5%, since the middle of February.
There is so much Canadian cannabis investment money right now that it is cascading down into the United States and Canadian investors are easily outbidding domestic acquirers.
Canadian marijuana stocks have been on a punishing slide for three straight months despite a temporary blip of investor fever in April that sent share prices soaring to record highs as Ottawa tabled legislation to legalize pot.
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
It is apparent that Aphria Inc. will be one of the major winners among marijuana companies. The timing of when to buy shares might be a bit tougher, though.
If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, decreased 15% in May as stocks sold off in both markets. This marks the worst performing month for the North American Marijuana Index since December 2015.
On June 1, 2017, High Times announced that controlling interest in the company had been acquired by 20 investors, a group comprised of cannabis industry members, entrepreneurs and entertainment veterans. Oreva Capital, a Los Angeles-based investment firm, led the High Times acquisition, valuing the company at $70 million. The company will now operate as High Times Holding Company.
How about another cannabis company to spark up your interest? Newstrike Ltd. is Canada’s newest pot stock that will be hitting the TSX Venture Exchange this Thursday.
First Trust Portfolios filed an S-6 on May 3oth with the Securities and Exchange Commission for a Medical Cannabis Portfolio Series – FT 6766 that is seeking above average capital appreciation.
Aurora Cannabis Inc. has been a favourite marijuana stock for some time. Should you be watching closely for an opportunity to buy the dip?
There are a handful of legitimate cultivators at this time, and an intriguing small-cap company is Aphria Inc. This marijuana stock is currently trading around $4.00, with a market cap of $579.3 million.
Cara Therapeutics has been phenomenal over the past couple of years, and it’s rightfully beginning to catch the attention of marijuana stock investors.
There are many reasons why Canopyis falling faster than its peers, but a big reason is the fact that Canopy was one of the first firms to the party. Canopy was one of the only ways to invest in the emerging marijuana industry, but now it is just one of many options to get in on the marijuana party.
Orlando trial lawyer and Amendment 2 financier John Morgan is prepared to invest $100 million in Florida’s medical marijuana industry.
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
On May 23, 2017, Hound Labs Inc., a marijuana breathalyzer company in Oakland, announced that it has closed its Series B round of financing with $8.1 million from Benchmark, a California-based venture capital firm that has made successful early-stage investments in companies like Uber and Snapchat, among others.
Last week, two marijuana stocks skyrocketed by a double-digit percentage. Let’s take a closer look at the possible “why” behind these moves.
On May 19, 2017, the U.S. Securities and Exchange Commission announced the temporary suspension of two marijuana stocks that trade on the OTC Markets, with both orders of suspension related to the companies neglecting to provide accurate and up-to-date information.
The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.